Halifax Biomedical Inc. Announces Additions to Executive Management Team
January 21, 2014

Nova Scotia – January 15, 2014 – Halifax Biomedical Inc. (HBI), a Nova Scotia based company that specializes in precision assessment of spine and joint-replacement micro-instability announces three additions to its Executive Management Team.


I am very pleased to announce the addition of three talented and experienced individuals to our executive management team, John Simon as COO, Godfrey Marchand as CFO and Dr. Erik Giphart as CTO” says HBI CEO Chad Munro. “HBI is moving into a critical stage of company development. I am confident these three individuals will elevate HBI to the next level of performance as we expand our operational and R&D programs.”


John Simon will be joining HBI as Chief Operating Officer (COO).  John is an experienced business executive operating in both multinational organizations and entrepreneurial start-up businesses. His previous work includes Vice President roles in business development and operations in a wide range of industries including information technology, healthcare, energy, and government. As COO, John will be responsible for growth of domestic and international sales and scaling of operations in line with market expansion.


HBI appoints Dr. Erik Giphart as Chief Technology Officer (CTO). Erik is a Biomedical Engineer and scientist with extensive experience in orthopaedic and joint motion research, design and development of advanced imaging techniques and devices, algorithm development, and biomechanics. Most recently he was Senior Staff Scientist, and Director of the BioMotion Laboratory at the Steadman Philippon Research Institute responsible for developing and completing independent research lines and projects in the areas of orthopaedics, injury prevention, biomechanics and motion capture.  As CTO, Erik’s responsibilities include overseeing clinical and regulatory affairs, managing corporate Intellectual Property strategy, and driving innovation.


Godfrey Marchand will now assume the role of Chief Financial Officer (CFO).  An entrepreneur and senior executive with strong financial management, corporate governance, and general management experience in the health care industry, Mr. Marchand was a co-founder and Vice President of Corporate Affairs at Zelos Therapeutics Inc. where he led the initial venture financing rounds. Godfrey has already been a strong contributor to HBI’s success as VP Finance. In his new position he will play a key role in the strategic development and financing of the company as it moves forward with expansion into the US and Central Canadian markets.



Halifax Biomedical Inc.

Halifax Biomedical Inc. (HBI) is an evidencebased Orthopaedic diagnostics company headquartered in Nova Scotia, Canada with US offices located in Cambridge, MA.


HBI is a world leading provider of micro-instability assessment services using very precise proprietary Stereo Radiography (SR) imaging technology (HALIFAX exams).


HBI focuses on two clinical problems: detection of implant loosening for total hip and knee replacements, and quantification of instability of the spinal column in patients with chronic low back pain.


For more information, please contact:


Chad Munro, CEO

Email: chad.munro@apps.halifaxbiomedical.com

Office: +1 (902) 945-2762

Fax: +1 (902) 945-2324